抗抑郁症新药γ-氨基丁酸A型受体变构调节剂珠兰诺隆研究进展  

Research progress on zuranolone, a new γ-aminobutyric acid type A receptor allosteric modulator for treatment of depression

作　　者：张亚安 王钰坤 沈薇 ZHANG Yaan;WANG Yukun;SHEN Wei(Department of Pharmaceutical and Chemical Engineering,Southeast University Chengxian College,Nanjing 210088,Jiangsu Province,China)

机构地区：[1]东南大学成贤学院制药与化学工程学院,江苏南京210088

出　　处：《世界临床药物》2023年第9期990-993,1011,共5页World Clinical Drug

基　　金：江苏省高等学校大学生实践创新训练计划项目(SCX22052);江苏省青蓝工程优秀青年骨干教师培养资助(2023);江苏高校哲学社会科学研究一般项目(2023SJYB0659);东南大学成贤学院国家级科研项目培育基金(2022NCF001)。

摘　　要：珠兰诺隆(zuranolone)是一种新型神经活性类固醇药物,通过对γ-氨基丁酸A型受体正向变构调节发挥作用,有望成为抑郁症(depression)新疗法。Ⅲ期临床研究显示,以一日1次口服、疗程2周的治疗方案,珠兰诺隆可快速改善抑郁症状,且总体耐受性良好。该文主要介绍珠兰诺隆的药理作用、药代动力学、安全性及临床研究进展。Zuranolone is a new neuroactive steroid drug,which acts on the positive allosteric modulation ofγ-aminobutyric acid type A receptor,and is expected to become a new treatment for depression.The results of phaseⅢclinical trials showed that zuranolone could rapidly improve depressive symptoms with the treatment of oral administration once a day for 2 weeks,and the overall tolerance was good.This article reviewed the pharmacological action,pharmacokinetics,safety and clinical research progress in zuranolone.

关 键 词：抑郁症 γ-氨基丁酸A型受体变构调节剂 珠兰诺隆 

分 类 号：R971.43[医药卫生—药品] R749.41[医药卫生—药学]